Premium
Apheresis techniques in lymphokine‐activated killer cell production
Author(s) -
Sniecinski Irena,
Sentinella Kim,
Margolin Kim,
Mills Bonnie
Publication year - 1988
Publication title -
journal of clinical apheresis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.697
H-Index - 46
eISSN - 1098-1101
pISSN - 0733-2459
DOI - 10.1002/jca.2920040214
Subject(s) - apheresis , medicine , lymphokine activated killer cell , lymphokine , interleukin 2 , immunology , cancer , peripheral blood mononuclear cell , immunotherapy , adoptive cell transfer , cytotoxic t cell , adoptive immunotherapy , population , regimen , t cell , platelet , cytokine , immune system , interleukin 21 , in vitro , biochemistry , chemistry , environmental health
Adoptive transfer of autologous lymphokine‐activated killer cells (LAK) in conjunction with recombinant interleu‐kin‐2 (rIL‐2) has been reported to produce significant regression in metastatic disease in patients with advanced cancer. In an effort to confirm the results reported by the Surgery Branch of the National Cancer Institute, the same IL‐2/LAK regimen was used in cancer patients at six extramural cancer centers. In this report we will review our experience with mononuclear cell removal from the blood of cancer patients using apheresis technology and extracorporeal handling of these cells to generate a selective, highly cytotoxic cell population.